bioAffinity Technologies, Inc. last reported quarterly results on Aug 7, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.5 million (+19.0% year over year) and diluted EPS of -$0.64. It usually reports 38–72 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 38–72 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 7, 2026
38 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
2
+19.0%
|
-3
+17.1%
|
-0.64
+87.4%
|
|
May 8, 2026
38 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
-27.1%
|
-4
-36.5%
|
-0.81
+83.1%
|
|
Mar 13, 2026
72 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
2
-27.8%
|
-3
-5.7%
|
-0.71
+88.2%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
-38.5%
|
-5
-152.4%
|
-4.74
+2.1%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
-47.1%
|
-4
-92.4%
|
-5.07
-2568.4%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
-23.0%
|
-3
-35.6%
|
-4.80
-2300.0%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
2
+687.4%
|
-2
+12.7%
|
-4.84
-1761.5%
|
|
Jul 9, 2024
9 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- BIAF (Nasdaq), BIAFW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc. (until Nov 3, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.